Literature DB >> 22811579

Cardiac fibrosis revisited by microRNA therapeutics.

Thomas Thum, Johan M Lorenzen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22811579     DOI： 10.1161/CIRCULATIONAHA.112.125013

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  19 in total

Review 1.  Advances in exploring the role of microRNAs in the pathogenesis, diagnosis and therapy of cardiac diseases in China.

Authors:  Z W Pan; Y J Lu; B F Yang
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

Review 2.  An emerging role for the miR-26 family in cardiovascular disease.

Authors:  Basak Icli; Pranav Dorbala; Mark W Feinberg
Journal:  Trends Cardiovasc Med       Date:  2014-06-12       Impact factor: 6.677

3.  Preeclampsia Downregulates MicroRNAs in Fetal Endothelial Cells: Roles of miR-29a/c-3p in Endothelial Function.

Authors:  Chi Zhou; Qing-Yun Zou; Hua Li; Rui-Fang Wang; Ai-Xia Liu; Ronald R Magness; Jing Zheng
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

4.  MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells.

Authors:  Chen Xi Li; Nilesh P Talele; Stellar Boo; Anne Koehler; Ericka Knee-Walden; Jenna L Balestrini; Pam Speight; Andras Kapus; Boris Hinz
Journal:  Nat Mater       Date:  2016-10-31       Impact factor: 43.841

Review 5.  The next generation of therapeutics for chronic kidney disease.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Nat Rev Drug Discov       Date:  2016-05-27       Impact factor: 84.694

6.  SHIP-AHOY (Study of High Blood Pressure in Pediatrics: Adult Hypertension Onset in Youth).

Authors:  Brenda Mendizábal; Elaine M Urbina; Richard Becker; Stephen R Daniels; Bonita E Falkner; Gilad Hamdani; Coral D Hanevold; Stephen R Hooper; Julie R Ingelfinger; Marc Lande; Lisa J Martin; Kevin Meyers; Mark Mitsnefes; Bernard Rosner; Joshua A Samuels; Joseph T Flynn
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

Review 7.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart.

Authors:  Karl T Weber; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling
Journal:  Nat Rev Cardiol       Date:  2012-12-04       Impact factor: 32.419

Review 8.  Myofibroblast secretome and its auto-/paracrine signaling.

Authors:  Ritin Bomb; Mark R Heckle; Yao Sun; Salvatore Mancarella; Ramareddy V Guntaka; Ivan C Gerling; Karl T Weber
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-02-17

9.  Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.

Authors:  Johan M Lorenzen; Celina Schauerte; Anika Hübner; Malte Kölling; Filippo Martino; Kristian Scherf; Sandor Batkai; Karina Zimmer; Ariana Foinquinos; Tamas Kaucsar; Jan Fiedler; Regalla Kumarswamy; Claudia Bang; Dorothee Hartmann; Shashi K Gupta; Jan Kielstein; Andreas Jungmann; Hugo A Katus; Frank Weidemann; Oliver J Müller; Hermann Haller; Thomas Thum
Journal:  Eur Heart J       Date:  2015-04-21       Impact factor: 29.983

Review 10.  Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.

Authors:  Boris Hinz; David Lagares
Journal:  Nat Rev Rheumatol       Date:  2019-12-02       Impact factor: 20.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.